Eli Lilly & Co’s (NYSE:LLY) experimental insulin matched Sanofi’s SA (ADR) (NYSE:SNY) top-seller Lantus at controlling blood sugar while assisting patients to drop weight, a verdict that may offer Lilly an edge in the $20 billion diabetes marketplace.
The American Diabetes Association meeting released data confirmed that the patients with Type 2 diabetes taking Lilly’s treatment lost an average of 1.28 pounds after 12 weeks evaluated against a weight lift of 0.68 pounds with Lantus.
The new insulin is being developed with Boehringer Ingelheim GmbH as piece of a pact the two companies struck in 2011 to work on diabetes medicines.
Shifting readers focus to broader market, let’s consider market performance of other stocks that significantly affect same sector. Sanofi SA (ADR) (NYSE:SNY) decreased -0.70% to settle at $34.19, AstraZeneca plc (ADR) (NYSE:AZN) moved down -0.61% to end at $41.04 while Bristol Myers Squibb Co. (NYSE:BMY) plunged -0.55% to finish on Monday at $34.18.
Eli Lilly & Co. (NYSE:LLY) last session volume of 5.60 million shares was surprisingly lower than its average volume of 7.25 million shares. The stock after opening at $41.74 hit high price of $41.91 and then closed at $41.49 by scoring -0.10%.
LLY generated revenue of 24.05 billion in the following twelve months and earned $4.30 billion. The Company showed a negative 17.89% in the net profit margin and as well as in its operating margin which remained 22.50%. Company’s annual sales growth for the past five year was 9.13%.
The LLY past twelve months price to sales ratio was 2.00 and price to cash ratio remained 9.78. As far as the returns are concern, the LLY return on equity was recorded as 29.91% and dropped 17.30% return on investment while its return on asset stayed at 13.46%.
The stock showed weekly upbeat performance of +3.34% which was maintained for the month at +0.56%. Likewise the positive performance for the quarter was recorded as +5.49% and for the year was +17.94% while the YTD performance remained at +2.29%.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL
